Fri Sep 20 08:42:56 UTC 2024: ## Y-mAbs Therapeutics Insider Sells Shares, Institutional Investors Adjust Holdings

**New York, NY** – Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) saw a recent insider transaction, with Thomas Gad, an insider, selling 65,000 shares on September 13th at an average price of $13.47, totaling $875,550. Following the sale, Gad now owns 97,681 shares of the company.

The news comes amidst a flurry of activity from institutional investors. Ameritas Investment Partners Inc. increased its stake in Y-mAbs Therapeutics by 39.9% during the first quarter, while China Universal Asset Management Co. Ltd. raised its stake by 66.1% in the same period. XTX Topco Ltd and Caxton Associates LP both acquired new positions in the company during the second and first quarters, respectively. Price T Rowe Associates Inc. MD also increased its holdings in the company by 8.5% during the first quarter. Institutional investors now own 70.85% of Y-mAbs Therapeutics’ stock.

Analysts have been weighing in on the company as well. Truist Financial initiated coverage on Y-mAbs Therapeutics with a “buy” rating and a $21.00 price objective, while Wedbush reiterated an “outperform” rating and issued a $23.00 price objective. Canaccord Genuity Group upgraded shares to a “strong-buy” rating, while Morgan Stanley dropped its price target from $12.00 to $11.00 and set an “underweight” rating. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective. Overall, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company, focuses on developing and commercializing antibody-based therapeutic products for cancer treatment. Its flagship product, DANYELZA, treats pediatric patients with relapsed or refractory high-risk neuroblastoma.

**Disclaimer:** This news article is based on publicly available information and is for informational purposes only. It does not constitute investment advice.

Read More